| Literature DB >> 20373694 |
David Nanchen1, Arnaud Chiolero, Pedro-Manuel Marques-Vidal, Jacques Cornuz, Gérard Waeber, Peter Vollenweider, Nicolas Rodondi.
Abstract
Primary prevention of cardiovascular disease by physicians is achieved by management of individual risk factors. The eligibility for treatment with statins is based on both an estimate of the risk of developing cardiovascular disease and the LDL-cholesterol. Three risk scores are commonly used: the PROCAM score, the Framingham score, and the European score. In Switzerland, the Swiss Group Lipids and Atherosclerosis (GSLA) recommends to use the PROCAM score with an adjustment of the level of risk for Switzerland. A survey also showed that PROCAM is the most used in Switzerland. In this article, the differences of these scores and their practical applications regarding the prescription of statins in primary prevention are discussed. The consequences and potential benefits of applying these scores in Switzerland are also discussed.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20373694
Source DB: PubMed Journal: Rev Med Suisse ISSN: 1660-9379